Table 3. Univariate and multivariate analysis of factors affecting ADT duration prior to CRPC onset.
| Variable | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p-value | HR | 95% CI | p-value | |
| Age | 0.986 | 0.969-1.003 | 0.104 | - | - | - |
| Diabetes mellitus | 1.521 | 1.025-2.256 | 0.037 | 1.573 | 1.019-2.430 | 0.041 |
| Hypertension | 1.025 | 0.879-1.025 | 0.879 | - | - | - |
| Body mass index | 0.992 | 0.939-1.049 | 0.789 | - | - | - |
| Hypercholesterolemia | 0.998 | 0.993-1.002 | 0.288 | - | - | - |
| Statin use (yes vs. no) | 0.709 | 0.507-0.993 | 0.045 | 0.613 | 0.414-0.908 | 0.015 |
| Biopsy Gleason score | ||||||
| 7 | Reference | - | - | Reference | - | - |
| 8 | 1.285 | 0.654-2.523 | 0.467 | 1.005 | 0.465-2.174 | 0.989 |
| 9 | 1.812 | 0.931-3.528 | 0.080 | 1.919 | 0.898-4.102 | 0.092 |
| 10 | 2.942 | 1.416-6.114 | 0.004 | 3.184 | 1.426-7.108 | 0.005 |
| PSA level at diagnosis | 1.000 | 1.000-1.000 | 0.459 | - | - | - |
| Metastasis type (bone vs. bone and viscera) | 1.093 | 0.535-2.232 | 0.809 | - | - | - |
ADT, androgen deprivation therapy; CRPC, castration-resistant prostate cancer; HR, hazard ratio; CI, confidence interval; PSA, prostate-specific antigen.